| ID Source | ID |
|---|---|
| PubMed CID | 10090192 |
| CHEMBL ID | 97080 |
| SCHEMBL ID | 12572388 |
| SCHEMBL ID | 18495719 |
| MeSH ID | M0413199 |
| Synonym |
|---|
| CHEMBL97080 |
| cd666 |
| cd-666 , |
| gtpl2652 |
| 4-[(e)-3-hydroxy-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid |
| cd 666 |
| bdbm31888 |
| SCHEMBL12572388 |
| 144006-45-1 |
| SCHEMBL18495719 |
| Q27075805 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Retinoic acid receptor alpha | Homo sapiens (human) | EC50 (µMol) | 0.3700 | 0.0002 | 0.1790 | 2.5119 | AID1380632 |
| Retinoic acid receptor alpha | Homo sapiens (human) | Kd | 1.5360 | 0.0002 | 0.5268 | 9.5000 | AID1799183 |
| Retinoic acid receptor beta | Homo sapiens (human) | EC50 (µMol) | 0.1400 | 0.0003 | 0.2311 | 6.9000 | AID1380634 |
| Retinoic acid receptor beta | Homo sapiens (human) | Kd | 1.5360 | 0.0002 | 0.2876 | 2.3000 | AID1799183 |
| Retinoic acid receptor gamma | Homo sapiens (human) | EC50 (µMol) | 0.0460 | 0.0002 | 0.0613 | 0.6480 | AID1380631 |
| Retinoic acid receptor gamma | Homo sapiens (human) | Kd | 1.5360 | 0.0002 | 0.4245 | 3.8240 | AID1799183 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1380635 | Selectivity index, ratio of EC50 for GAL4 DNA-binding domain-tagged RARbeta (unknown origin) ligand-binding domain expressed in human HG5LN cells to EC50 for GAL4 DNA-binding domain-tagged RARgamma (unknown origin) ligand-binding domain expressed in human | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. |
| AID1380633 | Selectivity index, ratio of EC50 for GAL4 DNA-binding domain-tagged RARalpha (unknown origin) ligand-binding domain expressed in human HG5LN cells to EC50 for GAL4 DNA-binding domain-tagged RARgamma (unknown origin) ligand-binding domain expressed in huma | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. |
| AID1380638 | Unbound fraction in plasma (unknown origin) | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. |
| AID1380631 | Agonist activity at GAL4 DNA-binding domain-tagged RARgamma (unknown origin) ligand-binding domain expressed in human HG5LN cells incubated for 18 hrs by luciferase reporter gene assay | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. |
| AID1380632 | Agonist activity at GAL4 DNA-binding domain-tagged RARalpha (unknown origin) ligand-binding domain expressed in human HG5LN cells incubated for 18 hrs by luciferase reporter gene assay | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. |
| AID1380634 | Agonist activity at GAL4 DNA-binding domain-tagged RARbeta (unknown origin) ligand-binding domain expressed in human HG5LN cells incubated for 18 hrs by luciferase reporter gene assay | 2018 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10 | Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. |
| AID1799183 | Retinoid Competition Binding Assay from Article 10.1006/jmbi.2000.4032: \\Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.\\ | 2000 | Journal of molecular biology, Sep-08, Volume: 302, Issue:1 | Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. |
| AID1346788 | Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors) | 1992 | Biochemical and biophysical research communications, Jul-31, Volume: 186, Issue:2 | Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. |
| AID1346786 | Human Retinoic acid receptor-beta (1B. Retinoic acid receptors) | 1992 | Biochemical and biophysical research communications, Jul-31, Volume: 186, Issue:2 | Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. |
| AID1346740 | Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors) | 1992 | Biochemical and biophysical research communications, Jul-31, Volume: 186, Issue:2 | Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (49.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||